CRNX Jan 2025 65.000 call
| Previous close | 4.5000 |
| Open | N/A |
| Bid | 0.5500 |
| Ask | 3.8000 |
| Strike | 65.00 |
| Expiry date | 2025-01-17 |
| Day's range | 4.5000 - 4.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
GuruFocus.comInsider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...
Following this transaction, the insider now owns 80,643 shares of the company. The recent transaction is part of a broader trend observed at Crinetics Pharmaceuticals Inc, where there have been 26 insider sells and no insider buys over the past year. Shares of Crinetics Pharmaceuticals Inc were priced at $45.37 on the day of the transaction, giving the company a market cap of approximately $3.33 billion.
GlobeNewswireEY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
Celebrating the bold leaders who disrupt markets, revolutionize industries and transform livesSAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Ernst & Young LLP (EY US) today announced that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, was named an Entrepreneur Of The Year® 2024 Pacific Southwest Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies. Dr. Struthers was selected by an indep
GuruFocus.comInsider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ...
Chief Scientific Officer Stephen Betz of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) sold 3,000 shares of the company on June 10, 2024, according to a recent SEC Filing.
